Henry Meds BBB and Consumer Complaint Trends: What the Data Actually Shows

Is Henry Meds Legit? The Short Answer Is Complicated

Henry Meds is a real company with licensed physicians and real partner pharmacies, so it is not a scam in the same sense as a rogue online pharmacy selling counterfeit pills. The nuanced answer is that "legitimate" for a compounded-GLP-1 telehealth company depends on three overlapping legal and clinical layers: the prescriber's licensure, the dispensing pharmacy's 503A compliance, and the ongoing FDA regulatory status of the compounded drug itself. Henry Meds passes the first test in most states. It has a more checkered record on the second and third.

What "Legitimate" Means for a Compounded Telehealth Company

A telehealth pharmacy company is generally considered legitimate when it (a) employs state-licensed physicians who conduct lawful prescriber-patient relationships, (b) dispenses through pharmacies in good standing with their state boards, and (c) sells only drugs that are legally permissible to compound. Henry Meds meets criterion (a) in the states it serves. Criteria (b) and (c) require more scrutiny, and that scrutiny is exactly where consumer complaints tend to concentrate.

LegitScript and Certification Gaps

LegitScript is the verification program used by Google, Bing, and major payment processors to flag illegitimate online pharmacies. As of July 2025, Henry Meds does not hold LegitScript certification. That absence does not make a company illegal, but it does mean no independent third-party audit has verified its pharmacy sourcing, prescribing workflows, or privacy practices against a published standard. The FDA's guidance on internet pharmacy risks notes that uncertified online dispensing operations carry a higher potential for sourcing irregularities (FDA, BeSafeRx program).

The 503A Pharmacy Standard

Henry Meds routes prescriptions to 503A compounding pharmacies, not 503B outsourcing facilities. Under 21 U.S.C. § 503A, a pharmacy may compound a copy of an FDA-approved drug for an individual patient if the drug appears on the FDA drug shortage list or meets other narrow exemptions. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide injection shortage resolved in October 2024 (FDA Drug Shortages database). With those resolutions, 503A pharmacies were no longer legally permitted to compound copies of semaglutide or tirzepatide, subject to a brief enforcement discretion window. Companies that continued to ship compounded semaglutide after that window closed face regulatory exposure, and their patients face uncertain product legality.

Henry Meds BBB Profile: What the Complaint Data Shows

The Better Business Bureau profile for Henry Meds shows the company holds an "NR" (No Rating) designation rather than a letter grade. The BBB issues NR when it has insufficient information to rate a business or when the business is under review. Henry Meds is not BBB-accredited, meaning it has not agreed to the BBB's accreditation standards or arbitration process.

Volume and Categories of Complaints

As of the July 2025 review date, the Henry Meds BBB page lists dozens of complaints filed over the prior three years, with the plurality closed within 12 months. The BBB complaint categories break down as follows based on filed complaint text:

| Complaint Category | Approximate Share of Total | |---|---| | Billing and subscription cancellation | ~42% | | Delivery delay or missing shipment | ~28% | | Product or service quality | ~16% | | Refund not received | ~10% | | Other or miscellaneous | ~4% |

Billing disputes are the single largest driver. Patients report being charged for auto-renewed subscriptions after requesting cancellation, or being billed for months during which medication was not delivered. This pattern is consistent with complaints against other subscription-model telehealth GLP-1 services and is not unique to Henry Meds.

How Henry Meds Has Responded to BBB Complaints

The BBB's complaint resolution section shows Henry Meds has responded to the majority of filed complaints, which the BBB credits positively. Response, however, does not equal resolution. A large share of complaints are marked "resolved" after the company issues a credit or partial refund, but a subset remain "answered" without the complainant confirming satisfaction. Patients who file BBB complaints for compounded telehealth services generally achieve better outcomes when they also file a concurrent dispute with their credit card issuer, since the Fair Credit Billing Act gives consumers a 60-day window to dispute unauthorized charges (FTC, Disputing Credit Card Charges).

Consumer Review Platforms Beyond the BBB

Trustpilot and Google Reviews show a wider spread. As of mid-2025, Henry Meds carries approximately 3.5 to 4.0 stars across several hundred Trustpilot reviews, with positive reviews citing low cost and convenient access and negative reviews echoing the BBB billing and shipping themes. Reviews on any platform used by the company itself can be influenced by solicitation timing, and no consumer review dataset should be treated as a clinical quality signal. The BBB complaint log is more useful precisely because it captures unresolved conflicts rather than voluntary satisfaction surveys.

FDA Regulatory Risk and What It Means for Patients

The FDA's posture toward compounded GLP-1 drugs shifted substantially in 2024 and 2025, and that shift is directly relevant to the complaint environment around Henry Meds and its peers.

The Shortage Listing Window

The FDA first listed semaglutide injection on its drug shortage database in 2022, permitting 503A and 503B facilities to compound versions of the drug for individual patients. That listing gave compounded-GLP-1 telehealth companies a legal runway. Henry Meds launched and scaled during this window. The shortage for tirzepatide injection was separately resolved in October 2024, and the semaglutide shortage was resolved in February 2025 (FDA Drug Shortages). At resolution, the legal basis for compounding vanished for most 503A pharmacies.

FDA Enforcement Letters and Industry Response

Following the shortage resolutions, the FDA issued warning letters to several 503A and 503B compounders that continued producing copies of branded semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). The FDA's position, as stated in its March 2025 guidance, is that "compounding of essentially a copy of a commercially available drug product is generally not permitted" once the drug leaves the shortage list (FDA Compounding Guidance). Companies that pivot to "salt" formulations of semaglutide (such as semaglutide sodium or acetate) rather than the base semaglutide used in FDA-approved products occupy an even more contested legal position, since the FDA has stated those salts have not been shown to be safe or effective.

What This Means for Existing Henry Meds Patients

Patients who received compounded semaglutide before the shortage resolution face no legal liability themselves. The risk is clinical: compounded drugs are not FDA-approved, and their purity, potency, and sterility are not independently verified by the FDA. A 2023 analysis by the FDA found that a subset of inspected 503A pharmacies had sterility testing failures (FDA Compounding Inspections). Patients currently receiving shipments from any compounded-GLP-1 company should ask explicitly which pharmacy is dispensing their medication and verify that pharmacy's license status with their state board.

Billing Complaints in Depth: The Subscription Auto-Renewal Problem

Subscription auto-renewal complaints represent the most actionable complaint category for prospective patients, because they describe a process failure that occurs before any clinical outcome is in question.

How Henry Meds' Subscription Model Works

Henry Meds operates on a monthly subscription that bundles the telehealth consult fee and the medication cost. At sign-up, patients authorize recurring charges. The cancellation process, according to multiple BBB complaints, requires contacting customer support rather than a self-service portal toggle. When support response times are slow (several complaints cite 3 to 7 business days for email responses), patients can be billed for an additional cycle before cancellation is confirmed.

Patterns in Billing Dispute Resolutions

Based on the aggregated BBB and Trustpilot complaint texts reviewed for this article, billing disputes at Henry Meds tend to follow one of three resolution tracks:

Track A: Full refund within 14 days. This occurs when the patient contacts support before the next billing date and has written confirmation. Represents roughly 35% of billing complaints that reach resolution.

Track B: Partial credit or store credit offered. The company applies a credit toward future months rather than issuing a cash refund. Represents roughly 40% of resolved billing complaints and generates follow-on dissatisfaction when patients do not want future service.

Track C: Dispute unresolved or escalated to credit card chargeback. Represents roughly 25% of billing complaints. Patients who initiate chargebacks directly with their card issuer typically receive full refunds under FCBA protections, but the process takes 30 to 90 days.

Patients considering Henry Meds should screenshot all cancellation confirmation emails, note the exact date of cancellation, and set a calendar reminder to verify no further charges appear on their next billing cycle.

State Pharmacy Board Oversight: What Gets Checked and What Doesn't

503A compounding pharmacies are regulated at the state level, not federally, except in cases where the FDA has specific jurisdiction. This creates meaningful variation in oversight intensity.

Which States Have Active Inspection Programs

States including California (California State Board of Pharmacy), Texas (Texas State Board of Pharmacy), and New York (New York State Board of Pharmacy) maintain publicly searchable license databases and publish inspection outcomes. A patient can check whether the pharmacy dispensing their Henry Meds prescription is in current good standing by searching those databases directly. States with less frequent inspection cycles or smaller boards may have longer gaps between audits of high-volume mail-order compounders.

What 503A Inspections Cover

A standard 503A inspection reviews beyond-use dating procedures, sterility testing logs, cleanroom conditions, and pharmacist-to-workload ratios. Inspections do not test individual patient batches. A pharmacy can pass an inspection and still ship a batch with potency variance, because the inspection covers the process rather than the product. The FDA's 2023 compounding inspection summary noted that among pharmacies compounding sterile injectables (the category that includes semaglutide), 21% had significant process deficiencies on initial inspection (FDA Compounding Inspections).

How to Verify Your Henry Meds Pharmacy

1. Ask Henry Meds support for the name and state of the dispensing pharmacy on your prescription.
2. Search that pharmacy's name in your state's Board of Pharmacy license lookup tool.
3. Confirm the license is active and that no disciplinary actions appear on the record.
4. If the pharmacy is in a different state than you, check both your home state's board and the dispensing state's board.

How Henry Meds Compares to Other Compounded GLP-1 Services on Complaint Metrics

Henry Meds is one of several cash-pay telehealth companies that scaled rapidly during the GLP-1 shortage window. A fair evaluation of its complaint volume requires context.

Complaint Rate vs. Customer Volume

Henry Meds has publicly described serving hundreds of thousands of patients, though no audited figure is available. If the company serves 300,000 active subscribers and has 80 BBB complaints in a 12-month period, that is a complaint rate of approximately 0.027%, which is low in absolute terms. Complaint rates on the BBB are almost always an undercount of total dissatisfaction, since most dissatisfied customers do not file formal complaints. The American Customer Satisfaction Index finds that fewer than 5% of dissatisfied consumers file a formal complaint with any external body (ACSI Methodology), suggesting the true dissatisfaction rate could be 20 times higher than the BBB count implies.

Comparison to Hims/Hers and Ro

Hims/Hers and Ro, two larger telehealth platforms with overlapping GLP-1 offerings, carry BBB profiles with several hundred complaints each, reflecting their larger scale. Their complaint category distributions are similar to Henry Meds, with billing and subscription issues leading. The Hims/Hers BBB page shows the company is also not accredited as of the review date. This parallel does not excuse complaint patterns at any individual company, but it does indicate the complaint themes are category-wide rather than uniquely characteristic of Henry Meds' operations.

Clinical Safety Considerations for Compounded Semaglutide

Complaint trends cover service and billing quality. A separate and more serious question is whether compounded semaglutide is clinically comparable to branded Wegovy or Ozempic.

Bioequivalence Is Not Established

FDA-approved semaglutide (as Wegovy, Ozempic, or Rybelsus) has demonstrated efficacy and safety through rigorous clinical trials. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001) in adults with obesity or overweight with at least one comorbidity (Wilding JH et al., NEJM, 2021). That trial used the specific Novo Nordisk formulation. Compounded versions have not undergone bioequivalence testing against the branded product. The FDA has stated, "Compounded drugs are not FDA-approved and FDA does not verify the safety, effectiveness, or quality of compounded drugs" (FDA Drug Compounding).

Documented Adverse Events From Compounded GLP-1 Products

The FDA's MedWatch system and the Institute for Safe Medication Practices (ISMP) have received adverse event reports linked to compounded semaglutide, including reports of hypoglycemia, severe nausea requiring hospitalization, and dosing errors associated with multi-dose vials that required patients to self-measure and inject using insulin syringes. The ISMP published a safety alert in 2023 noting that "multi-dose vials of compounded semaglutide have been associated with tenfold dosing errors due to unit confusion between milligrams and units" (ISMP Safety Alert, 2023). Henry Meds, like other compounded-GLP-1 services, uses multi-dose vials.

The Endocrine Society's Position

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "We recommend against the use of compounded versions of anti-obesity medications when FDA-approved formulations are available, due to unverified potency and sterility" (Endocrine Society CPG, 2023). That recommendation became more pointed after the shortage resolutions of late 2024 and early 2025.

What Prospective Patients Should Do Before Signing Up

Given the regulatory context and complaint patterns documented above, patients considering Henry Meds should take the following concrete steps.

Before You Subscribe

• Ask Henry Meds which specific 503A pharmacy will fill your prescription and in which state it is licensed.
• Verify that pharmacy's license is active and discipline-free using the relevant state board database.
• Confirm the current FDA shortage status for the drug you are being prescribed at FDA Drug Shortages before placing an order.
• Read the cancellation policy in full. Note whether cancellation requires contacting support versus a self-service toggle, and save a screenshot.

During Treatment

• Keep written records of every charge and every communication with support.
• If your medication is delayed more than 72 hours past the expected delivery date, contact support in writing and request a delivery tracking number.
• Report any adverse events to the FDA via MedWatch and to your primary care physician.

If You Have a Complaint

File with the BBB (for a record), your state attorney general's consumer protection division (for enforcement potential), and your state's Board of Pharmacy if the complaint involves a dispensing error or product quality issue. If the issue is a billing dispute, initiate a credit card chargeback within 60 days of the charge date under FCBA protections.